Abstract 249P
Background
Pain and cough are the two commonest presenting symptoms in lung cancer, with an incidence of 51% and 65%, causing significant distress to the patient and caretakers. This study highlights the impact of opioid analgesics and adjuncts in relieving symptom burden and eventual improvement in cough specific quality of life.
Methods
This retrospective study comprises 107 lung cancer patients under JIPMER palliative registry from Jan-2019 till Oct-2021. Survival and QOL data were collected from patients and caretakers via telephone. Clinical data was collected from medical records. Symptom burden was assessed with the Visual Analog Scale and Cough VAS scale, while cough-QOL was assessed with the MCLCS (Manchester Cough in Lung Cancer Scale) at the time of clinical follow up.
Results
Comparing the data of patients who had received opioid analgesics without adjuncts (n=25), the patients who had received opioid analgesics (n=82) along with adjuncts (Gabapentin 600 mg/day and Amitriptyline 25 mg/day), had a better cough relief (19% v 45%) and improved cough QOL (20% v 32%). G+A subgroup showed a 20.7% reduction of mean baseline morphine dose at subsequent visits. Gabapentin subgroup had a 10% reduction of mean baseline dose. Reduction in mean cough VAS in opioids only group Vs Opioid + Adjunct group is 17.3% Vs 40.4%. Gabapentin subgroup has 39% reduction while G+A subgroup has 40.6% reduction in the mean cough VAS. Reduction in Mean MCLCS score in opioids only group Vs Opioid + Adjunct group is 17.8% Vs 35.5%. Per the MCLCS, in the gabapentin subgroup has 36.6% reduction while G+A subgroup has 27.3% reduction.
Conclusions
Inferring from the above data, patients with adjuncts have better mean cough VAS and QOL according to the MCLCS questionnaire, in addition to reduction in overall pain, when compared to patients who received only opioids for their pain. In addition to primary treatment with radiotherapy and chemotherapy, palliative care forms a core component in management of lung cancers and their symptom burden. Antitussive properties of opioids appear to be accentuated when given along with adjuncts. The efficacy of adjuncts, though well studied in other chronic cough conditions, need to be evaluated further in thoracic malignancies, especially lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract